Human herpesvirus 6 (HHV-6) has been frequently isolated from immunocompromised patients. To determine if a routine survey of HHV-6 infection is needed after organ transplantation, as is the case for human cytomegalovirus infection, we observed patients who had received kidney, liver, and kidney-liver transplants; these patients were followed up for the first 3 months after transplantation. HHV-6 infection was diagnosed by isolation of the virus and by the results of serological tests. Antibodies to HHV-6 were detected in 28 (87.5%) of the 32 recipients, before the transplant, whereas only 4 (12.5%) of the 32 recipients were seronegative for HHV-6. After engraftment, HHV-6 infection occurred in 10 (31%) of the 32 recipients; infection was diagnosed by isolation of the virus (6 of 32 recipients) or by the results of serological tests (4 of 32 recipients). Regardless of whether they had HHV-6 primary infection or reactivation, severe clinical manifestations were observed only in patients who had concomitant cytomegalovirus infection, and no correlation could be found between graft rejection and HHV-6 infection. These results suggest that HHV-6 infection occurs frequently in organ transplant recipients and that it is usually not associated with severe clinical manifestations unless accompanied by a concomitant CMV infection.
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Human herpesvirus 6 (HHV-6) was isolated for the first time in 1986 from the blood of patients with lymphoproliferative disorders [1] . More than 80% ofthe adult population worldwide is infected with HHV-6. Primary infections occur early in childhood and may cause exanthema subitum. All other herpesviruses, and especially human cytomegalovirus (CMV), have been implicated as a primary cause of morbidity and mortality in immunosuppressed transplant recipients. HHV-6 infections have also been reported in organ transplant recipients [2, 3] . To determine if HHV-6 could account for clinical manifestations observed in organ transplant recipients, we performed a longitudinal study based on isolation of both HHV-6 and CMV.
Methods
We observed 32 patients between 22 and 68 years of age during the first 3 months after transplantation. The 3-month follow-up consisted of weekly clinical and laboratory (measurement of serum creatinine and bilirubin concentrations) evaluations. To isolate HHV-6 and to analyze serological tests for the presence of HHV-6, peripheral blood samples were harvested 1 week before transplantation, at the time of transplantation, and then weekly thereafter during the three 3 months after transplantation. Transplant recipients had kidney disease (glomerulonephritis, interstitial nephropathy, polycystic disease), liver disease (alcoholic cirrhosis, viral cirrhosis, hepatocellular carcinoma), or diabetes. Eighteen of the 32 transplant recipients received a kidney, 11 received a liver, and 3 received a combined transplant (one underwent a kidney-pancreas transplant, one a heart-kidney-pancreas transplant, and one a liverpancreas transplant).
The immunosuppressive regimen for all transplant recipients other than the kidney and kidney-pancreas recipients consisted of a combination of cyclosporine, azathioprine, and prednisone; the kidney and kidney-pancreas recipients also received antithymocyte globulins. Cyclosporine therapy was administered on day 4 after transplantation. Mild rejections were treated by methylprednisolone, and severe rejections were treated with OKT3 monoclonal antibodies. Peripheral blood mononuclear cells were isolated from the patients' heparinized blood by Ficoll-Hypaque separation (Pharmacia, Uppsala, Sweden) and cultivated as reported previously [1] . The cultures were examined twice weekly by optical microscopy to detect the typical HHV-6 cytopathic effect, which consists of large refractile cells. HHV-6 isolates were identified by PCR as reported previously by Buchbinder et a1. [4] . HHV-6 serological analysis was performed by standard immunofluorescence assay as reported previously [5] . Isolation of CMV was performed on urine, blood (buffy coat), or bronchoalveolar lavage specimens according to the method described by Mazeron et a1. [6] . 
Results
Before transplantation, 28 (87.5%) of the 32 recipients were seropositive for HHV-6. With use of both virus isolation and analysis of serological results, 10 cases ofHHV-6 infection were demonstrated among the 32 transplant recipients (31%) during the first 3 months after transplantation (tables I and 2). Primary infections occurred in all four patients who were seronegative for HHV-6 before transplantation (table I and figure I; patients 1-4). Taking into account serologic cross-reactivity between HHV-6 and CMV [7] , the diagnosis ofprimary HHV-6 infection might be difficult to confirm, especially in cases of concomitant CMV infection and in cases in which HHV-6 is not isolated from blood. The six other infections, which occurred in patients who had antibodies to HHV-6 before transplantation, could be considered as reactivations (table 2 and figure 2; patients 5-10).
Regardless of whether they had HHV-6 primary infection or reactivation, severe symptoms occurred only in patients who had concomitant CMV infection (patients 1,3,5, and 9). In the absence of a concomitant CMV infection, symptoms were either absent or mild (patients 2, 4, 6, 8, and 10); the only exception was patient 7, who died of acute renal failure that probably was not related to HHV-6 infection. We did not find any correlation between HHV-6 infection and rejection of the graft since the difference in graft rejection between the patients who were infected with HHV-6 (40%) and those who were not infected (38%) was not statistically significant (P >.05, X 2 test with
Yates' correction) (data not shown). The prevalence of HHV-6 infection did not increase during OKT3 monoclonal antibody therapy for rejections (P >.05) (data not shown).
Discussion
All four patients with primary infection received organs from donors who were seropositive for HHV -6. Although transmission of HHV-6 infection by blood transfusion cannot be ruled out, the fact that HHV -6 was previously isolated from a transplanted kidney suggests that the virus was probably present in the transplant tissue. Viral reactivation, which has been observed in six patients, probably occurred because of the immunosuppressive treatment. Regardless ofwhether they had HHV-6 primary infection or reactivation, severe symptoms occurred only in patients with concomitant CMV infection. Severe clinical manifestations, such as hemorrhagic colitis, myocarditis, pneumonitis, or hepatitis, are usually attributed to CMV infections, although these infections might be induced by HHV-6-related immunosuppression. However, the role of HHV -6 in inducing these manifestations cannot be ruled out since pneumonitis and hepatitis have also been reported in immunocompromised patients who are infected with HHV-6 [8, 9] .
The fact that transplant recipients recover from severe symptoms after being treated with ganciclovir does not exclude the role of HHV-6 in inducing these manifestations since HHV-6 is usually sensitive to the antiviral agents (e.g., ganciclovir, phosphonofonnate) used for the treatment of CMV infection. Fever was observed in patients who were infected with both HHV-6 and CMV and could be attributed to each of these viruses [2] . In contrast with other data that report a close association between HHV-6 infection and kidney rejection [3] , we did not find an increase in the frequency of graft rejection in patients who were infected with HHV -6. Detection of HHV-6 by in situ hybridization and quantification of the viral load in the rejected tissue by PCR should highlight the exact role of HHV-6 in transplant rejection. In contrast with the increased frequency of CMV infections during transplant rejections treated with OKT3 monoclonal antibodies, the prevalence of HHV -6 infection was not modified by OKT3 treatment
(P >.05).
This study provides evidence that, during the first 3 months after an organ transplantation, severe clinical manifestations occur only in patients who are concomitantly infected with HHV-6 and CMV and that there seems to be a lack of correlation between HHV-6 infection and transplant rejection. Further studies will be necessary to specify the exact role of HHV-6 infection in organ transplant recipients; these studies will have to focus on quantification of the viral load in blood and target tissues.
